AnaCardio is developing a new form of drug concept that protects cardiac tissue in conjunction with heart failure. AnaCardio’s clinical candidate drug is being developed to restore the heart’s normal muscular function and blood circulation with ground-breaking and safer technique than currently available treatment options. The Company’s goal is to develop an oral drug that in contrast to existing treatments can affect the underlying cause of disease. AnaCardio was founded based on ground-breaking research from Karolinska Institutet.